Current Filters

Showing 31 - 40 results of 3489

Simeprevir (Galexos) (Last Updated: Aug 22, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Galexos
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:

Hepatitis C, chronic

Phleum pratense (Grastek) (Last Updated: Sep 30, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Grastek
Manufacturer:
Merck Canada Inc.
Submission Type:
Initial
Indications:

Allergy (grass)

Rotigotine (Neupro) (Last Updated: Jul 31, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Neupro
Manufacturer:
UCB Canada Inc.
Submission Type:
Initial
Indications:

Parkinson’s Disease

Aclidinium bromide (Tudorza Genuair) (Last Updated: Aug 21, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Tudorza Genuair
Manufacturer:
Almirall Canada Ltd.
Submission Type:
Initial
Indications:

Chronic Obstructive Pulmonary Disease (COPD)

Guanfacine hydrochloride (Intuniv XR) (Last Updated: Aug 27, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Intuniv XR
Manufacturer:
Shire Canada Inc.
Submission Type:
Initial
Indications:

Attention-deficit/hyperactivity disorder (ADHD)

OnabotulinumtoxinA (Botox) (Last Updated: Aug 15, 2013)

Request for Resubmission: Eligible (Decision Date: June 5, 2018)
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Botox
Manufacturer:
Allergan Inc.
Submission Type:
Initial
Indications:

Migraine, chronic

Eplerenone (Inspra) (Last Updated: Jul 12, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Inspra
Manufacturer:
Pfizer Canada Inc.
Submission Type:
Initial
Indications:

Heart failure, NYHA class II

Golimumab (Simponi) (Last Updated: Jul 12, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Simponi
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:

Ulcerative colitis

Tocilizumab (Actemra) (Last Updated: Jul 29, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Actemra
Manufacturer:
Hoffmann-La Roche Limited
Submission Type:
Initial
Indications:

Polyarticular juvenile idiopathic arthritis

Saxagliptin + metformin (Komboglyze) (Last Updated: Jun 6, 2013)

Project Line:
Reimbursement Review
Project Status:
Withdrawn
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Komboglyze
Manufacturer:
Bristol-Myers Squibb / AstraZeneca Canada Inc.
Submission Type:
Initial
Indications:

Diabetes Mellitus, Type 2

Download results as CSV